Volume 4 Number 1
Website Exclusive Contents!
Editorial
2
Percutaneous Cardiovascular Intervention. The time has come for a big change...EuroInterv.2008;4:17-21
3
Chronic total coronary occlusions and the Occluded Artery Trial. A critical appraisal.Werner G, Di Mario C, Galassi A, Gershlick A, Reimers B, Sianos G, Sievert H, Lefèvre T, Reifart N, for the EuroCTO Club
EuroInterv.2008;4:23-27
EAPCI column
Focus article
8
Cardiovascular repair and regeneration 2008: the Fourth International Conference on Cell Therapy for Cardiovascular Disease (IC3D)EuroInterv.2008;4:47-49
9
Highlights from ICI-Innovations in Cardiovascular Interventions. December 3-5, 2007, Tel Aviv, IsraelEuroInterv.2008;4:50-52
Clinical research
10
EXCELLA™ First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesionsCosta Júnior J, Abizaid A, Feres F, Costa R, Seixas A, Maia F, Abizaid An, Tanajura L, Staico R, Siqueira D, Meredith L, Bhat V, Yan J, Ormiston J, Sousa A, Fitzgerald P, Sousa J
EuroInterv.2008;4:53-58
11
Biodegradable-polymer-based, sirolimus-eluting Supralimus® stent: 6-month angiographic and 30 month clinical follow-up results from the Series I prospective studyEuroInterv.2008;4:59-63
12
Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up studyDirksen M, Vink M, Suttorp M, Tijssen J, Patterson M, Slagboom T, Kiemeneij F, Laarman G, for the Paclitaxel-Eluting Stent versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation (PASSION) investigators
EuroInterv.2008;4:64-70
13
Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month resultsGrube E, Sievert H, Hauptmann K-E, Mueller R, Gerckens U, Buellesfeld L, Ako J, Shimohama T, Costa M, Fitzgerald P
EuroInterv.2008;4:71-76
14
Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-DELFT)Meliga E, García-García H, Valgimigli M, Chieffo A, Biondi-Zoccai G, O'Maree A, Gonzalo N, Cook S, Cruz-Gonzalez I, Marra S, De Servi S, Palacios I, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW
EuroInterv.2008;4:77-83
15
European experience with the retrograde approach for the recanalisation of coronary artery chronic total occlusions. A report on behalf of the EuroCTO clubSianos G, Barlis P, Di Mario C, Papafaklis M, Büttner J, Galassi A, Schofer J, Werner G, Lefèvre T, Louvard Y, Serruys PW, Reifart N
EuroInterv.2008;4:84-92
16
Impact of bifurcation lesions on clinical outcome and prognosis of primary angioplasty in acute myocardial infarctionAbdel Hakim D-E, Garot P, Champagne S, Maklady F, El Hawary A, Dubois-Randé J-L, Lesault P-F, Teiger E
EuroInterv.2008;4:93-98
17
Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic resultsEuroInterv.2008;4:99-107
18
Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesionsEuroInterv.2008;4:108-114
Expert review
19
The role of thrombectomy and distal protection devices during percutaneous coronary interventionsEuroInterv.2008;4:115-123
20
Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug-eluting stentsRivero F, Moreno R, Barreales L, Galeote G, Sánchez-Recalde A, Calvo L, Jimenez-Valero S, Villate A, Vanegas M, López-Sendón J-L
EuroInterv.2008;4:124-132
Experimental research
21
Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarctionvan Beem R, Hirsch A, Lommerse I, Zwaginga J, Noort W, Biemond B, Piek J, van der Schoot C, Voermans C
EuroInterv.2008;4:133-138
22
The neointimal response to stents eluting Tacrolimus from a degradable coating depends on the balance between polymer degradation and drug releaseEuroInterv.2008;4:139-147
Technical report
23
Percutaneous aortic valve implantation utilising a novel tissue valve: preclinical experience EuroInterv.2008;4:148-153
24
Development of IMRISCardio™, an integrated, interventional angio-MR Imaging Suite EuroInterv.2008;4:154-157
25
Medical positioning system: a technical report Flugelman M, Shiran A, Nusimovici-Avadis D, Schwartz L, Herscovici A, Cohen A, Shofti R, Lewis B, Luchner A, Jeron A
EuroInterv.2008;4:158-160
Volume 4 Number 1 has been released thanks to the support of the following partners:
- Abbott Vascular Devices
- Atrium Medical
- Biosensors
- Cardiac Assist Inc.
- Cordis, a Johnson & Johnson company
- Hexacath
- Invatec
- Medtronic
- Merit Medical
- Terumo
- Xtent Inc.
- Zoll Medical Corporation


